- $5.52bn
- $5.27bn
- $383.48m
- 73
- 15
- 41
- 38
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.2 | ||
| Price to Tang. Book | 12.62 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 14.39 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -13.6% | ||
| Return on Equity | -23.83% | ||
| Operating Margin | -31.91% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 224.96 | 294.01 | 282.86 | 314.71 | 383.48 | 480.63 | 614.63 | 10.1% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.
Directors
- Thomas Burns CHM (60)
- Joseph Gilliam CFO (46)
- Chris Calcaterra COO (60)
- Mark Foley LED (55)
- David Hoffmeister IND (66)
- Gilbert Kliman IND (62)
- Marc Stapley IND (51)
- Denice Torres IND (61)
- Aimee Weisner IND (52)
- Leana Wen IND (38)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 14th, 1998
- Public Since
- June 25th, 2015
- No. of Shareholders
- 46
- No. of Employees
- 995
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
New York Stock Exchange- Shares in Issue
- 57,086,023
- Address
- 1 GLAUKOS WAY, ALISO VIEJO, 92656
- Web
- https://www.glaukos.com
- Phone
- +1 9493679600
- Auditors
- Ernst & Young LLP
Upcoming Events for GKOS
Q1 2025 Glaukos Corp Earnings Call
Glaukos Corp Annual Shareholders Meeting
Glaukos Corp Annual Shareholders Meeting
Q2 2025 Glaukos Corp Earnings Release
Similar to GKOS
Abbott Laboratories
New York Stock Exchange
Agilent Technologies
New York Stock Exchange
Alcon AG
New York Stock Exchange
Artivion
New York Stock Exchange
Avanos Medical
New York Stock Exchange
FAQ
What is the Glaukos share price?
As of Today at 20:51 UTC, shares in Glaukos are trading at $96.68. This share price information is delayed by 15 minutes.
How has the Glaukos share price performed this year?
Shares in Glaukos last closed at $96.68 and the price had moved by -3.43% over the past 365 days. In terms of relative price strength the Glaukos share price has underperformed the S&P500 Index by -10.86% over the past year.
What are the analyst and broker recommendations for Glaukos?
The overall consensus recommendation for Glaukos is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Glaukos dividend yield?
Glaukos does not currently pay a dividend.
Does Glaukos pay a dividend?
Glaukos does not currently pay a dividend.
When does Glaukos next pay dividends?
Glaukos does not currently pay a dividend.
How do I buy Glaukos shares?
To buy shares in Glaukos you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Glaukos?
As of the previous close price of $96.68, shares in Glaukos had a market capitalisation of $5.52bn.
Where are Glaukos shares listed?
Here are the trading details for Glaukos:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: GKOS
What kind of share is Glaukos?
Based on an overall assessment of its quality, value and momentum Glaukos is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Glaukos share price forecast for 2025?
The analyst consensus target price for shares in Glaukos is $154.31. That is 59.61% above the last closing price of $96.68.
Analysts covering Glaukos currently have a consensus Earnings Per Share (EPS) forecast of -$0.98 for the next financial year.
Find out moreWhat is the trend in the Glaukos share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Glaukos. Over the past six months, its share price has underperformed the S&P500 Index by -21.97%.
As of the last closing price of $96.68, shares in Glaukos were trading -24.76% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Glaukos PE Ratio?
The Glaukos PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $96.68.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Glaukos?
Glaukos' management team is headed by:
- Thomas Burns - CHM
- Joseph Gilliam - CFO
- Chris Calcaterra - COO
- Mark Foley - LED
- David Hoffmeister - IND
- Gilbert Kliman - IND
- Marc Stapley - IND
- Denice Torres - IND
- Aimee Weisner - IND
- Leana Wen - IND